We are relentless in OUR MISSION to end breast cancer.
NBCC advocates know it takes more than passion and compelling language to end breast cancer. We know we must also work together to act upon a complex yet focused strategic plan of action. Our plan is led by advocates who have no other agenda than to save lives, and each year NBCC makes it clear that we not only understand what is needed but we can also overcome the barriers put in our way to get there. In 2021 we again faced, but refused to accept, the unrelenting reality that women and men continue to die from breast cancer. Many of them were dedicated to NBCC’s mission to end this disease. Their loss only strengthened our commitment to lead the way in recognizing that system change is needed within public policy, healthcare and research to stop breast cancer. In 2021 we again proved that we know how to make that change happen through the work highlighted on the following pages. While new challenges presented themselves in the form of an evolving pandemic, the breakout of another war abroad, and economic upheaval, we kept our programs and our advocacy focused on our agenda. We are proud to share some of NBCC’s 2021 accomplishments that reflect the relentless work of our advocates. We hope you remain steadfast with us. Together we can end breast cancer.

Frances M. Visco
President, National Breast Cancer Coalition

The National Breast Cancer Coalition Fund is the 501(c)(3) arm of NBCC that designs and runs programs to educate, train, and inform advocates, policymakers, scientists, providers, and the public about breast cancer science, health care, and advocacy. The Fund collaborates with the research community on innovative research, effects change in the health care system to advance access to quality health care for all and gives a powerful, effective voice to breast cancer advocates everywhere.

The National Breast Cancer Coalition, NBCC’s 501(c)(4) arm, sets a public policy agenda and then works to enact the necessary legislation, policy, and regulation to end breast cancer. The Coalition lobbies through its grassroots network for increased funding for innovative research, a seat at the table to oversee how those funds are spent, and public policies to expand access to quality health care for all.

WHO WE ARE

Our Mission is to save lives by ending breast cancer. We are a coalition of advocates determined to make this happen by insisting on system change. We question the status quo of breast cancer care and research.

Understanding scientific concepts and processes, as well as healthcare policies, at a level to make an impact takes commitment, education, training, and time. NBCC provides the highest quality advocacy training and education that empowers breast cancer survivors and others to take leadership roles in breast cancer research, healthcare, and public policy.

Together we continue to change the breast cancer landscape by shaping crucial innovative research and challenging public policy. Our accomplishments in 2021 demonstrate that when we work together, every dollar goes further in reaching our mission to end breast cancer.

VALUES

INCLUSION
We require diversity of thought, action and perspective in everything we do. We want everyone at the table.

INTEGRITY
We are committed to our mission and hold ourselves and others accountable for positions and actions taken.

QUESTIONING
We challenge the status quo, view everything with a critical eye and analyze all information before we act.

COURAGE
We ask hard questions and make difficult decisions. When the evidence dictates, we reject accepted thinking.

KNOWLEDGE
We do our homework and make strategic choices based on evidence.

URGENCY
We must end breast cancer now.

FOCUS
We strategize how to have meaningful impact; we bring about real change.

TENACITY
Until breast cancer is ended, we will never give up and will never back down.

INNOVATION
We challenge ourselves and others to create new models and approaches.

COMPASSION
No one else should suffer.
RESEARCH

Artemis Project — NBCC led our Artemis Project®, an innovative, mission-driven collaboration of advocates and scientists, in plans of action on Primary Prevention and the Prevention of Metastasis, at our first in-person meeting in two years in December. Extensive planning was done throughout the year to prepare for institutionalizing Artemis, including developing a comprehensive strategic plan.

Artemis Primary Prevention — NBCC continued to advance our preventive vaccine, which targets all three major subsets of breast cancer, in partnership with the NCI Prevent program. (The NCI PREVENT Program supports, in their words, the best in cancer prevention that addresses unmet needs not adequately addressed by the private sector.) We now expect to launch a Phase 1 Clinical Trial in late 2022/early 2023.

Artemis Preventing Metastasis — Artemis participants submitted a five-part proposal to the Cancer Research UK Grand Challenge program and helped expand the collaboration to include nanotechnology expertise. Artemis participants also trialed methods for purifying disseminated tumor cells from the bone marrow of breast cancer patients.

Clinical Trials — NBCC continued its collaboration with Translational Research In Oncology (TRIO) and Novartis on a clinical trial of CDK4/6 inhibitors in early high-risk HR+ breast cancer, the NATALEE trial. NBCC participated in its trial Steering Committee, the data safety monitoring board, and the translational research committee.

Outreach — NBCC participated in several national meetings on clinical trial and research issues such as the Accelerating Anticancer Agent Development and Validation Workshop, the Cancer Research UK Grand Challenge Summit, and the Integration Panel of the Department of Defense Breast Cancer Research Program.

NBCC testified on April 27, 2021, to the FDA Oncologic Drug Advisory Committee (ODAC), outlining its opposition to the continued accelerated approval of drugs that fail to demonstrate clinical benefit in confirmatory trials.

Artemis Advocate Literature Review — Advocates conducted a literature review to inform decision-making about the potential population for a Phase 2 preventive vaccine trial.

EDUCATION AND TRAINING

Project LEAD® is NBCC’s premier science training program. This program trains advocates in the fundamentals of breast cancer science, research design and the skills needed to participate in clinical trials and the decision-making process.

Project LEAD® Institute — NBCC hosted a free, virtual, week-long refresher course for more than 120 Project LEAD graduates. Topics covered biology and genetics, epidemiology, immunology, and clinical trial design.

Advanced Project LEAD — Existing Advanced LEAD advocates participated in an Artemis literature review for a Phase 2 preventive vaccine trial, prepared and testified at the April 27, 2021, FDA Oncologic Drug Advisory Committee meeting, and continued its cancer research models project.

Thank you for providing this opportunity to educate advocates. Project LEAD was an amazing learning opportunity and a fabulous experience.
Continuing Education — NBCC conducted numerous webinars such as “Clinical Oncology: How to find the most effective treatments for patients worldwide,” “Rapid COVID-19 Vaccine Development,” and “Advancing Model Development to Accelerate Breast Cancer Research.” NBCC also hosted two Advanced Topic Sessions for Project LEAD graduates: “CDK 4/6 Inhibitors in Breast Cancer (Advanced and Adjuvant Settings)” and “mRNA Vaccines in Breast Cancer Prevention and Treatment.”

Learning Management System (LMS) — NBCC expanded its Learning Management System to seven modules featuring materials on clinical trial methodology, patient-reported outcomes and measurement, ethical issues in clinical trials conduct, and screening mammography.

Advocate Leadership Summit — NBCC hosted more than 200 advocates at the Virtual Advocate Leadership Summit. Topics included an Update on NBCC’s Artemis Project, Solutions for Breast Cancer Disparities, “Warp Speed” Science, Breast Cancer Models and Precision Oncology, Immune Checkpoint Inhibitors, and the FDA Drug Approval Process. The program offered a special message from First Lady Dr. Jill Biden.

“The speakers were incredible. The detailed information shared about scientific data, the detailed discussion regarding the Metastatic Breast Cancer Act, meeting with the politicians in our district and others to ask for support of the bill, these were all invaluable to me as an advocate.”

PUBLIC POLICY

NBCC’s Public Policy advocacy increases federal funding for breast cancer research, monitors how research funds are spent, expands access to quality health care for all and ensures trained advocates influence all legislative decisions affecting breast cancer.

DOD Breast Cancer Research Program — In 1992, the Department of Defense Breast Cancer Research Program (DOD BCRP) started because of NBCC’s campaign to increase federal appropriations for breast cancer research. Through NBCC’s work Congress approved another $150 million for FY2022. NBCC’s national network has been integral to securing more than $4 billion in funding since this research program began in 1992.

Metastatic Breast Cancer Access to Care Act — NBCC’s advocates were responsible for obtaining strong bipartisan support for our priority legislation, S. 1312/H.R. 3183, the Metastatic Breast Cancer Access to Care Act. This bill would waive waiting periods for social security and Medicare for people living with metastatic breast cancer. NBCC initiated this bill and by year-end secured more than 190 cosponsors in the House and 23 in the Senate. Access to Affordable & Effective Therapies — In January, the NBCC Board approved a policy that addresses systemic deficiencies in the law, regulation, and science policy that result in drug approvals that do not significantly extend or save lives and whose prices are not based on value or effectiveness. In October, the Board adopted a set of principles for the evaluation of approaches to this issue.

Annual Membership Lobby Day — Advocates held more than 200 meetings with their members of Congress. Back in home districts, advocates attended virtual town halls and published letters to the editor in their local papers to advocate for NBCC’s priorities.

Project LEAD Public Policy — NBCC’s Project LEAD Public Policy trained grassroots advocates in the skills necessary to be informed and effective advocates for NBCC’s mission to end breast cancer. This two-day workshop educated advocates on, the process of policy development, how to determine which issues are appropriate for federal and state legislation, which should be part of the regulatory process, and which are better addressed outside of government.

“Project LEAD exceeded my expectations on every level. I truly feel I learned a great deal and made lifelong friends as well.”

The Summit offers the opportunity to learn about timely issues related to breast cancer — typically not presented at the mainstream medical conferences. Hearing the advocates’ perspective is always a reality check on the importance of our voice at the table where decisions are being made.”
### 2021 BOARD OF DIRECTORS

**ABCD: After Breast Cancer Diagnosis**
Bonnie Anderson (D), Ellen Friebert Schupper (A)

**Alamo Breast Cancer Foundation**
Jerry Worden (D), Beth Emery (A)

**American Association of Breast Care Professionals**
Rhonda Turner (D), Gretchen Walton (A)

**Annie Appleseed Project**
Ann Fonfa (D), Rasheedah Ahmad (A)

**Breast Cancer Care and Research Fund**
Michele Rakoff (D), Lori Petitti (A)

**CARE Advocates Network**
Carol Matyka (D), Karen Poliseno (A)

**Cedar Valley Cancer Committee: Beyond Pink TEAM**
Christine Carpenter (D), Lori Seawel (A)

**Cedars Sinai Breast Center**
Sherry Goldman (D), Sylvia Estrada (A)

**Delaware Breast Cancer Coalition, Inc.**
Francesca Vogel (D), Susan Murray (A)

**Dr. Susan Love Research Foundation**
Judith Hirshfield-Bartek (D), Christopher Clinton Conway (A)

**Florida Breast Cancer Foundation**
Valencia Robinson (D), Judy Perkins (A)

**Metropolitan Washington, DC Chapter of NBCC**
Wanda Lucas (D), Tania Chomiak-Salvi (A)

**Michigan Breast Cancer Coalition**
Rose Marie Sitko (D), Jeanne Deneweth (A)

**Minnesota Breast Cancer Coalition**
Christine Norton (D), Pat Haugen (A)

**National Breast Cancer Coalition**
Frances M. Visco (D)

**Nueva Vida**
Astrid J iménez, Esq. (D), Gloria Elliott (A)

**SHARE**
Ivis Febus-Sampayo (D)

**Virginia Breast Cancer Foundation**
Marylinn Minor (D), Katy Sawyer (A)

**Young Survival Coalition**
Joy Simha (D)

### NATIONAL BREAST CANCER COALITION

### BOARD OF TRUSTEES

**Alec R. Call**
Beth Emery, J D
Sherry Goldman RN, NP, MSN
Ira Hillman, **Treasurer**
Judith Hirshfield-Bartek, RN, MS, OCN
Bryan Johns
Liane Martins Lindner, **Chair**
Christine Norton, MA, **Secretary**
Michele Rakoff
Linda Rothweiler, DMD, **Vice Chair**
Dennis Slamon, MD, PhD
Frances M. Visco, J D, **NBCC President**
Carol Vance Wall
Ann C. Yahner, J D

### YOUR DOLLARS AT WORK

#### Assets 2021

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$3,033,626</td>
</tr>
<tr>
<td>Accounts Receivables</td>
<td>$1,486,599</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$257,998</td>
</tr>
<tr>
<td>Net Property &amp; Equipment</td>
<td>$51,726</td>
</tr>
<tr>
<td>Deposits</td>
<td>$0</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$4,829,949</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liabilities</td>
<td>$117,515</td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$4,712,434</strong></td>
</tr>
<tr>
<td><strong>Total Liabilities &amp; Assets</strong></td>
<td><strong>$4,829,949</strong></td>
</tr>
</tbody>
</table>

#### 2021 Expenses $2,790,063*

- 9% Grassroots, etc.
- 1% Other Programs
- 11% Fundraising
- 13% Public Policy
- 24% Catalytic Research
- 26% Education & Training
- 1% Management & General

#### 2021 Public Support & Other Revenue $4,452,514*

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>$1,053,865</strong></td>
<td>24% Individuals</td>
</tr>
<tr>
<td><strong>$1,108,295</strong></td>
<td>25% Special Events</td>
</tr>
<tr>
<td><strong>$854,358</strong></td>
<td>19% Restricted Grants</td>
</tr>
<tr>
<td><strong>$1,126,141</strong></td>
<td>25% Corporations &amp; Foundations</td>
</tr>
<tr>
<td><strong>$309,854</strong></td>
<td>7% Other Revenue</td>
</tr>
</tbody>
</table>

* Pie-chart reflects expenses of $2,790,063. It does not include event-related direct benefits to donors of $121,289.

* Total Expense and Total Revenue include event costs that are direct benefits to donors of $121,289.
NBCC’s signature annual fundraising events provide a unique opportunity for the community to support NBCC’s education and training, and research programs in a fun and entertaining environment.

2021 Cabaret Event
The Les Girls 2021 Cabaret event was held in person on October 24th on the grounds of Paramount Studios. NBCC honored Sherry Goldman with its advocacy award. Bryan Johns and Alec Call, NBCC Board Members and longtime supporters, whose company, iS Clinical, has been the title sponsor for the event for many years, were honored with the NBCC leadership award. This volunteer celebrity production is a showstopper and continues to sell out every year. A very special thank you to our committee members listed below.

Gerry Bernardi and Joe Keenan, Alec Call and Bryan Johns, Linda Essakow and Stephen Gunther, Sherry Goldman, Cindy Harrell-Horn and Alan Horn, Lonnie Israel, Blake Johns and Brit Shaw, Pamela Morton, Lauren Shuler Donner, Arleen Sorkin, Carol and Terry Wall

NYC Women With Balls®
The New York Women With Balls bowling event was held in person on November 9th at Frames NYC. Board member Liane Martins Lindner continued to serve as our Event Chair. This special program continues to grow in popularity and offers the opportunity for teams to have fun and compete in raising funds as well as on the bowling lane.

DONORS
Corporate and Foundation Donors of $5,000 or more

AbbVie Inc.
America’s Charities
Barbara Silver Levin Foundation
Boston Foundation
Cedars Sinai Breast Center
Combined Jewish Philanthropies
David Geffen Foundation
Exact Sciences (formerly Genomic Health, Inc.)
Facebook Payments Inc.
George and Amy Klette Newman Foundation
HCVT LLC
iS CLINICAL by INNOVATIVE SKINCARE
James and Deborah Burrows Foundation
Joyce and Irving Goldman Family Foundation
Judy & Peter Blum Kovler Foundation
Kline & Specter, P.C.
Mellam Family Foundation
Merck & Co., Inc.
Mueller Family Foundation
Novartis Oncology
Patient Centered Outcomes Research Institute
Peter Morton Foundation
Pfizer Inc.
R & L Donner Trust
Safra National Bank
Sevenwinds Casino, Lodge & Conference Center
St. Louis Breast Cancer Coalition
Steve Tisch Family Foundation
The Anbinder Family Foundation
The Biondi Family Fund
The Carole & Robert Daly Charitable Foundation
The Hall Charitable Trust
The Herbert McLaughlin Children’s Trust
The Horn Foundation
The Robert and Shirley Harris Family Foundation
The Rosenthal Family Foundation
The StudBuddy LLC
The Swedish American Chamber of Commerce of Washington DC, Inc.
The Wayne Gretzky Foundation
The Wonderful Company Foundation
Translational Research in Oncology-US, Inc. (TRIO-US)
TRIO Global
Vance Wall Foundation

* Please note individual donors are no longer listed in NBCC’s annual report.